The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - Polaris
Consulting or Advisory Role - Adaptimmune; Apexigen; Bayer; Caris Centers of Excellence; Cytokinetics; CytRx Corporation; Daiichi Sankyo; Epizyme; GlaxoSmithKline; Immune Design; Lilly; Pfizer; Plexxikon
Speakers' Bureau - Adaptimmune; Caris Centers of Excellence; GlaxoSmithKline; Janssen; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent on the use of ME1 as Biomarker. Patent on ALEXT#102.
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline
Other Relationship - OncLive
A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in patients with HER2-positive tumors.
 
Zev A. Wainberg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Monica M. Mita
Research Funding - Seagen (Inst)
 
Minal A. Barve
No Relationships to Disclose
 
Erika P. Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutter Medical Group (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Lilly; Pfizer; Puma Biotechnology
 
Andrew J. Brenner
Leadership - NanoTX
Stock and Other Ownership Interests - NanoTX; Plus Therapeutics
Honoraria - Vascular Biogenics
Consulting or Advisory Role - Alamab Therapeutics; NanoTX; Plus Therapeutics; Vascular Biogenics
Research Funding - Boston Biomedical (Inst); Immunomedics (Inst); Medicenna (Inst); miRNA Therapeutics (Inst); Threshold Pharmaceuticals; Upsher-Smith (Inst); Vascular Biogenics
Patents, Royalties, Other Intellectual Property - I have intellectual property interest in NanoTx Therapeutics
Travel, Accommodations, Expenses - Vascular Biogenics
 
Frances Valdes
Honoraria - Adverum (I); Allegro Ophthalmics (I); Allergan (I); BVI (I); EyePoint Pharmaceuticals (I); Genentech (I); Janssen Biotech (I); Novartis (I); Santen (I); Valeant Pharmaceuticals International (I)
Research Funding - Merck (Inst); Roche/Genentech (Inst)
 
Daniel H. Ahn
Consulting or Advisory Role - Celltrion (I); Eisai; Exelixis; Genentech/Roche
Research Funding - AstraZeneca; Bayer
 
Joleen M. Hubbard
Consulting or Advisory Role - Bayer (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); Hutchison MediPharma (Inst); Merck (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Treos Bio (Inst)
 
Jason S. Starr
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Ipsen; Natera; Pfizer
Research Funding - Incyte (Inst); Macrogenics (Inst); Merus (Inst); Molecular Templates (Inst); Natera; Rafael Pharmaceuticals (Inst); Vedanta Biosciences (Inst)
 
Christine Burnett
Employment - Molecular Templates
 
Joshua Pelham
Employment - Molecular Templates
 
Thomas Strack
Employment - Molecular Templates
 
Andres Machado
No Relationships to Disclose
 
Brian A. Van Tine
No Relationships to Disclose